CHDI
Accelerating Therapeutic Development for Huntington's Disease
NAARDEN, The Netherlands & WALTHAM, Mass. — May 26, 2026 — Prilenia Therapeutics B.V. today announced a Data Use Agreement (DUA) under which Prilenia will provide CHDI with clinical data from the placebo arms of its PRIDE and PROOF studies for the purpose of advancing research into treatments for Huntington’s disease (HD).
The Postcards are a series of video roundups aimed at non-scientists that convey the major themes, scientific breakthroughs, and clinical trial updates from conference series that CHDI organizes: the Huntington’s Disease Therapeutics Conference held (most usually) in Palm Springs, California in February, and the Huntington’s Disease Clinical Research Conference in collaboration alternately with the Huntington Study Group and the European Huntington’s Disease Network in the US and Europe in September/October. If you would like to post any of these Postcards on your website, please contact